FDA Advisory Committee Votes Against GSK's Blenrep in Multiple Myeloma on July 17, 2025 Advisory Committees Clinical Trials drug safety Eye Multiple Myeloma ODAC SmithKline Beecham Toxicity aspects United States Food and Drug Administration vote +